SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Joshua J. Gagne, Shirley V. Wang, Jeremy A. Rassen, Sebastian Schneeweiss, A modular, prospective, semi-automated drug safety monitoring system for use in a distributed data environment, Pharmacoepidemiology and Drug Safety, 2014, 23, 6
  2. 2
    David Madigan, Paul E. Stang, Jesse A. Berlin, Martijn Schuemie, J. Marc Overhage, Marc A. Suchard, Bill Dumouchel, Abraham G. Hartzema, Patrick B. Ryan, A Systematic Statistical Approach to Evaluating Evidence from Observational Studies, Annual Review of Statistics and Its Application, 2014, 1, 1, 11

    CrossRef

  3. 3
    Saurabh Zalpuri, Rutger A. Middelburg, Henk Schonewille, Karen M.K. Vooght, Saskia Cessie, Johanna G. Bom, Jaap Jan Zwaginga, Intensive red blood cell transfusions and risk of alloimmunization, Transfusion, 2014, 54, 2
  4. 4
    Joshua J. Gagne, Jeremy A. Rassen, Niteesh K. Choudhry, Rhonda L. Bohn, Amanda R. Patrick, Gayathri Sridhar, Gregory W. Daniel, Jun Liu, Sebastian Schneeweiss, Near-Real-Time Monitoring of New Drugs: An Application Comparing Prasugrel Versus Clopidogrel, Drug Safety, 2014, 37, 3, 151

    CrossRef

  5. 5
    Elisabetta Patorno, Amanda R. Patrick, Elizabeth M. Garry, Sebastian Schneeweiss, Victoria G. Gillet, Dorothee B. Bartels, Elvira Masso-Gonzalez, John D. Seeger, Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations, Diabetologia, 2014, 57, 11, 2237

    CrossRef

  6. 6
    Shirley V. Wang, Sebastian Schneeweiss, Jeremy A. Rassen, Optimal Matching Ratios in Drug Safety Surveillance, Epidemiology, 2014, 25, 5, 772

    CrossRef

  7. 7
    Jessica M. Franklin, Sebastian Schneeweiss, Jennifer M. Polinski, Jeremy A. Rassen, Plasmode simulation for the evaluation of pharmacoepidemiologic methods in complex healthcare databases, Computational Statistics & Data Analysis, 2014, 72, 219

    CrossRef

  8. 8
    Cynthia J Girman, Douglas Faries, Patrick Ryan, Matt Rotelli, Mark Belger, Bruce Binkowitz, Robert O’Neill, Pre-study feasibility and identifying sensitivity analyses for protocol pre-specification in comparative effectiveness research, Journal of Comparative Effectiveness Research, 2014, 3, 3, 259

    CrossRef

  9. 9
    Hirotaka Katada, Naoichiro Yukawa, Hisashi Urushihara, Shiro Tanaka, Tsuneyo Mimori, Koji Kawakami, Prescription patterns and trends in anti-rheumatic drug use based on a large-scale claims database in Japan, Clinical Rheumatology, 2014,

    CrossRef

  10. 10
    Lisa M. Kalisch Ellett, Nicole L. Pratt, John D. Barratt, Debra Rowett, Elizabeth E. Roughead, Risk of Medication-Associated Initiation of Oxybutynin in Elderly Men and Women, Journal of the American Geriatrics Society, 2014, 62, 4
  11. 11
    Nete Munk Nielsen, Henrik Svanström, Egon Stenager, Melinda Magyari, Nils Koch-Henriksen, Björn Pasternak, Anders Hviid, The use of valproic acid and multiple sclerosis, Pharmacoepidemiology and Drug Safety, 2014, 23, 12
  12. 12
    H. Svanstrom, B. Pasternak, A. Hviid, Use of strontium ranelate and risk of acute coronary syndrome: cohort study, Annals of the Rheumatic Diseases, 2014, 73, 6, 1037

    CrossRef

  13. 13
    Patrick B. Ryan, Paul E. Stang, J. Marc Overhage, Marc A. Suchard, Abraham G. Hartzema, William DuMouchel, Christian G. Reich, Martijn J. Schuemie, David Madigan, A Comparison of the Empirical Performance of Methods for a Risk Identification System, Drug Safety, 2013, 36, S1, 143

    CrossRef

  14. 14
    Xiaofeng Zhou, Sundaresan Murugesan, Harshvinder Bhullar, Qing Liu, Bing Cai, Chuck Wentworth, Andrew Bate, An Evaluation of the THIN Database in the OMOP Common Data Model for Active Drug Safety Surveillance, Drug Safety, 2013, 36, 2, 119

    CrossRef

  15. 15
    Giulia P. Consiglio, Andrea M. Burden, Malcolm Maclure, Lisa McCarthy, Suzanne M. Cadarette, Case-crossover study design in pharmacoepidemiology: systematic review and recommendations, Pharmacoepidemiology and Drug Safety, 2013, 22, 11
  16. 16
    Emil L. Fosbol, Comparative Effectiveness Research, Heart Failure Clinics, 2013, 9, 1, 37

    CrossRef

  17. 17
    Patrick B. Ryan, Martijn J. Schuemie, Susan Gruber, Ivan Zorych, David Madigan, Empirical Performance of a New User Cohort Method: Lessons for Developing a Risk Identification and Analysis System, Drug Safety, 2013, 36, S1, 59

    CrossRef

  18. 18
    David Madigan, Martijn J. Schuemie, Patrick B. Ryan, Empirical Performance of the Case–Control Method: Lessons for Developing a Risk Identification and Analysis System, Drug Safety, 2013, 36, S1, 73

    CrossRef

  19. 19
    E. Garbe, S. Kloss, M. Suling, I. Pigeot, S. Schneeweiss, High-dimensional versus conventional propensity scores in a comparative effectiveness study of coxibs and reduced upper gastrointestinal complications, European Journal of Clinical Pharmacology, 2013, 69, 3, 549

    CrossRef

  20. 20
    Patrick Ryan, Marc A. Suchard, Martijn Schuemie, David Madigan, Learning From Epidemiology: Interpreting Observational Database Studies for the Effects of Medical Products, Statistics in Biopharmaceutical Research, 2013, 5, 3, 170

    CrossRef

  21. 21
    R Harpaz, W DuMouchel, P LePendu, A Bauer-Mehren, P Ryan, N H Shah, Performance of Pharmacovigilance Signal-Detection Algorithms for the FDA Adverse Event Reporting System, Clinical Pharmacology & Therapeutics, 2013, 93, 6, 539

    CrossRef

  22. 22
    Torbjörn Callréus, Pharmacovigilance and Public Health Ethics, Pharmaceutical Medicine, 2013, 27, 3, 157

    CrossRef

  23. 23
    Sengwee Toh, Jerry Avorn, Ralph B. D'Agostino, Jerry H. Gurwitz, Bruce M. Psaty, Kenneth J. Rothman, Kenneth G. Saag, Miriam C. J. M. Sturkenboom, Jan P. Vandenbroucke, Almut G. Winterstein, Brian L. Strom, Re-using Mini-Sentinel data following rapid assessments of potential safety signals via modular analytic programs, Pharmacoepidemiology and Drug Safety, 2013, 22, 10
  24. 24
    Seoyoung C. Kim, Craig Newcomb, David Margolis, Jason Roy, Sean Hennessy, Severe Cutaneous Reactions Requiring Hospitalization in Allopurinol Initiators: A Population-Based Cohort Study, Arthritis Care & Research, 2013, 65, 4
  25. 25
    B. Pasternak, H. Svanstrom, K. Schmiegelow, T. Jess, A. Hviid, Use of Azathioprine and the Risk of Cancer in Inflammatory Bowel Disease, American Journal of Epidemiology, 2013, 177, 11, 1296

    CrossRef

  26. 26
    Henrik Svanström, Björn Pasternak, Anders Hviid, Use of Azithromycin and Death from Cardiovascular Causes, New England Journal of Medicine, 2013, 368, 18, 1704

    CrossRef

  27. You have free access to this content27
    Bruce Fireman, Sengwee Toh, Melissa G. Butler, Alan S. Go, Hylton V. Joffe, David J. Graham, Jennifer C. Nelson, Gregory W. Daniel, Joe V. Selby, A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent, Pharmacoepidemiology and Drug Safety, 2012, 21,
  28. 28
    Jan M. Friedman, ABCDXXX: The obscenity of postmarketing surveillance for teratogenic effects, Birth Defects Research Part A: Clinical and Molecular Teratology, 2012, 94, 8
  29. 29
    Joshua J. Gagne, Jeremy A. Rassen, Alexander M. Walker, Robert J. Glynn, Sebastian Schneeweiss, Active Safety Monitoring of New Medical Products Using Electronic Healthcare Data, Epidemiology, 2012, 23, 2, 238

    CrossRef

  30. 30
    J J Gagne, R J Glynn, J A Rassen, A M Walker, G W Daniel, G Sridhar, S Schneeweiss, Active Safety Monitoring of Newly Marketed Medications in a Distributed Data Network: Application of a Semi-Automated Monitoring System, Clinical Pharmacology & Therapeutics, 2012, 92, 1, 80

    CrossRef

  31. 31
    Joshua J. Gagne, Alexander M. Walker, Robert J. Glynn, Jeremy A. Rassen, Sebastian Schneeweiss, An Event-Based Approach for Comparing the Performance of Methods for Prospective Medical Product Monitoring, Pharmacoepidemiology and Drug Safety, 2012, 21, 6
  32. 32
    Marcia Valenstein, Hyungjin Myra Kim, Dara Ganoczy, Daniel Eisenberg, Paul N. Pfeiffer, Karen Downing, Katherine Hoggatt, Mark Ilgen, Karen L. Austin, Kara Zivin, Frederic C. Blow, John F. McCarthy, Antidepressant Agents and Suicide Death Among US Department of Veterans Affairs Patients in Depression Treatment, Journal of Clinical Psychopharmacology, 2012, 32, 3, 346

    CrossRef

  33. 33
    Jeremy A. Rassen, Robert J. Glynn, Kenneth J. Rothman, Soko Setoguchi, Sebastian Schneeweiss, Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses, Pharmacoepidemiology and Drug Safety, 2012, 21, 7
  34. 34
    Marianne Hamilton Lopez, Erin Holve, Indra Neil Sarkar, Courtney Segal, Building the Informatics Infrastructure for Comparative Effectiveness Research (CER), Medical Care, 2012, 50, S38

    CrossRef

  35. 35
    Krista F. Huybrechts, Sebastian Schneeweiss, Tobias Gerhard, Mark Olfson, Jerry Avorn, Raisa Levin, Judith A. Lucas, Stephen Crystal, Comparative Safety of Antipsychotic Medications in Nursing Home Residents, Journal of the American Geriatrics Society, 2012, 60, 3
  36. 36
    Brian D. Bradbury, David T. Gilbertson, M. Alan Brookhart, Ryan D. Kilpatrick, Confounding and Control of Confounding in Nonexperimental Studies of Medications in Patients With CKD, Advances in Chronic Kidney Disease, 2012, 19, 1, 19

    CrossRef

  37. You have free access to this content37
    Jennifer M. Polinski, Sebastian Schneeweiss, Robert J. Glynn, Joyce Lii, Jeremy A. Rassen, Confronting “confounding by health system use” in Medicare Part D: comparative effectiveness of propensity score approaches to confounding adjustment, Pharmacoepidemiology and Drug Safety, 2012, 21,
  38. You have free access to this content38
    Joshua J. Gagne, Bruce Fireman, Patrick B. Ryan, Malcolm Maclure, Tobias Gerhard, Sengwee Toh, Jeremy A. Rassen, Jennifer C. Nelson, Sebastian Schneeweiss, Design considerations in an active medical product safety monitoring system, Pharmacoepidemiology and Drug Safety, 2012, 21,
  39. 39
    D Yoon, M Y Park, N K Choi, B J Park, J H Kim, R W Park, Detection of Adverse Drug Reaction Signals Using an Electronic Health Records Database: Comparison of the Laboratory Extreme Abnormality Ratio (CLEAR) Algorithm, Clinical Pharmacology & Therapeutics, 2012, 91, 3, 467

    CrossRef

  40. 40
    P. Juillerat, S. Schneeweiss, E. F. Cook, A. N. Ananthakrishnan, H. Mogun, J. R. Korzenik, Drugs that inhibit gastric acid secretion may alter the course of inflammatory bowel disease, Alimentary Pharmacology & Therapeutics, 2012, 36, 3
  41. 41
    R Harpaz, W DuMouchel, N H Shah, D Madigan, P Ryan, C Friedman, Novel Data-Mining Methodologies for Adverse Drug Event Discovery and Analysis, Clinical Pharmacology & Therapeutics, 2012, 91, 6, 1010

    CrossRef

  42. 42
    S. Zalpuri, J. J. Zwaginga, S. le Cessie, J. Elshuis, H. Schonewille, J. G. van der Bom, Red-blood-cell alloimmunization and number of red-blood-cell transfusions, Vox Sanguinis, 2012, 102, 2
  43. You have free access to this content43
    Robert J. Glynn, Joshua J. Gagne, Sebastian Schneeweiss, Role of disease risk scores in comparative effectiveness research with emerging therapies, Pharmacoepidemiology and Drug Safety, 2012, 21,
  44. 44
    Marc Suling, Iris Pigeot, Signal Detection and Monitoring Based on Longitudinal Healthcare Data, Pharmaceutics, 2012, 4, 4, 607

    CrossRef

  45. You have free access to this content45
    Andrea J. Cook, Ram C. Tiwari, Robert D. Wellman, Susan R. Heckbert, Lingling Li, Patrick Heagerty, Tracey Marsh, Jennifer C. Nelson, Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the Mini-Sentinel pilot, Pharmacoepidemiology and Drug Safety, 2012, 21,
  46. 46
    Sebastian Schneeweiss, Jeremy A Rassen, Robert J Glynn, Jessica Myers, Gregory W Daniel, Joseph Singer, Daniel H Solomon, SeoYoung Kim, Kenneth J Rothman, Jun Liu, Jerry Avorn, Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments, BMC Medical Research Methodology, 2012, 12, 1, 180

    CrossRef

  47. 47
    J Morris, The Use of Observational Health-Care Data to Identify and Report on Off-Label Use of Biopharmaceutical Products, Clinical Pharmacology & Therapeutics, 2012, 91, 5, 937

    CrossRef

  48. 48
    Björn Pasternak, Henrik Svanström, Nete M Nielsen, Mads Melbye, Anders Hviid, Use of amiloride and multiple sclerosis: registry-based cohort studies, Pharmacoepidemiology and Drug Safety, 2012, 21, 8
  49. You have free access to this content49
    Jeremy A. Rassen, Sebastian Schneeweiss, Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system, Pharmacoepidemiology and Drug Safety, 2012, 21,
  50. 50
    S Schneeweiss, J J Gagne, R J Glynn, M Ruhl, J A Rassen, Assessing the Comparative Effectiveness of Newly Marketed Medications: Methodological Challenges and Implications for Drug Development, Clinical Pharmacology & Therapeutics, 2011, 90, 6, 777

    CrossRef

  51. 51
    J. A. Rassen, R. J. Glynn, M. A. Brookhart, S. Schneeweiss, Covariate Selection in High-Dimensional Propensity Score Analyses of Treatment Effects in Small Samples, American Journal of Epidemiology, 2011, 173, 12, 1404

    CrossRef

  52. 52
    Seo Young Kim, Sebastian Schneeweiss, Jeffrey N Katz, Raisa Levin, Daniel H Solomon, Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort, Journal of Bone and Mineral Research, 2011, 26, 5
  53. 53
    Torbjörn Callréus, The New EU Legislation on Pharmacovigilance and Changing Models for Drug Development, Drug Safety, 2011, 34, 6, 529

    CrossRef

  54. 54
    Current awareness: Pharmacoepidemiology and drug safety, Pharmacoepidemiology and Drug Safety, 2010, 19, 12
  55. 55
    Sebastian Schneeweiss, Samy Suissa, Advanced Approaches to Controlling Confounding in Pharmacoepidemiologic Studies,
  56. 56
    Sebastian Schneeweiss, Samy Suissa, Advanced Approaches to Controlling Confounding in Pharmacoepidemiologic Studies,
  57. 57
    John Acquavella, Brian Bradbury, Cathy Critchlow, J. Michael Sprafka, John Sullivan, Jason B. Litten, Pharmacoepidemiology as Part of Pharmacovigilance for Biologic Therapies,